SCHEMBL23124186

SCHEMBL23124186

COc1nc(C2CCCCC2)cn1COCC[Si](C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.36
PDE10A Q9Y233 2/20 0.32
EGFR P00533 1/20 0.31
IGF1R P08069 1/20 0.31
SRC P12931 1/20 0.31
FLT4 P35916 1/20 0.31
KDR P35968 1/20 0.31
FLT3 P36888 1/20 0.31
EPHB4 P54760 1/20 0.31
TEK Q02763 1/20 0.31
KLKB1 P03952 1/20 0.31
NPC1 O15118 2/20 0.30
RAB9A P51151 2/20 0.30
S1PR1 P21453 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23123420 0.99 DGAT1 (0.37) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL23124163 0.86 DGAT1 (0.36) DGAT1
SCHEMBL23123826 0.84 DGAT1 (0.34) DGAT1EGFRIGF1RSRCFLT4
SCHEMBL23124318 0.81 DGAT1 (0.33) DGAT1PDE10A
SCHEMBL23124170 0.74 DGAT1 (0.42) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL23124184 0.74 DGAT1 (0.45) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL23124316 0.73 DGAT1 (0.32) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL12302216 0.73 DGAT1 (0.35) DGAT1KLKB1
SCHEMBL17592021 0.72 DGAT1 (0.44) DGAT1PDE10AKLKB1
SCHEMBL23123823 0.72 NPC1 (0.36) DGAT1PDE10AEGFRIGF1RSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 US disclosed
EP-4031531-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
CN-114787135-A Substituted imidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed
WO-2021055612-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL-BioTech Investments, Inc. (US) 2021-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, CLN6 DGAT1 3633/4885PDE10A 2939/4885EGFR 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.